| Liu, Jihong |
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 393 | RoW | IMP4927, Placebos | Impact Therapeutics, Inc. | Ovarian Cancer | 02/22 | 12/22 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
SHR-1701-III-309, NCT05179239: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer |
|
|
| Recruiting | 3 | 572 | RoW | SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Cervical Cancer | 03/24 | 05/25 | | |
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 498 | RoW | QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin | Qilu Pharmaceutical Co., Ltd. | METASTATIC CERVICAL CANCER | 09/24 | 07/25 | | |
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
NCT04864782: QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer |
|
|
| Terminated | 2/3 | 46 | RoW | QL1604, PD-1 monoclonal antibody, Paclitaxel injection, Cisplatin/Carboplatin | Qilu Pharmaceutical Co., Ltd. | Cervical Cancer | 09/22 | 11/23 | | |
NCT05557565: A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer |
|
|
| Recruiting | 2 | 150 | RoW | QL1706 | Qilu Pharmaceutical Co., Ltd. | Cervical Cancer | 10/22 | 06/23 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
AK3280-2002, NCT05424887: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | 2 | 105 | RoW | AK3280, Placebo | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Idiopathic Pulmonary Fibrosis | 07/24 | 10/24 | | |
| Recruiting | 2 | 100 | RoW | SHR-A2102 for injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Gynecological Malignancy | 08/25 | 10/26 | | |
NCT05434897: A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | AK3280 Cream, AK3287, Placebo cream | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Hypertrophic Scar | 07/23 | 11/23 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05779163: A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 468 | RoW | LBL-033 for Injection, LBL-033 | Nanjing Leads Biolabs Co.,Ltd | Advanced Malignant Tumors | 03/26 | 03/26 | | |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
